Reuters logo
Amgen profit tops expectations on Enbrel sales, tax credit
2015年1月27日 / 晚上9点13分 / 3 年前

Amgen profit tops expectations on Enbrel sales, tax credit

Jan 27 (Reuters) - Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit, driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel, cost cutting and a tax credit.

The world’s largest biotechnology company posted a net profit of $1.29 billion, or $1.68 per share, compared with a profit of $1.02 billion, or $1.33 per share, a year ago.

Excluding items, Amgen earned $2.16 per share. Analysts on average expected $2.05, according to Thomson Reuters I/B/E/S.

The results were helped by a research and development tax credit that came through in the quarter and added about 10 cents per share to earnings, the company said.

Revenue rose 6 percent to $5.33 billion, edging past Wall Street estimates of $5.19 billion. (Reporting by Bill Berkrot; Editing by Diane Craft)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below